Mylan launches chronic hepatitis B tablets in India
New Delhi: Drug firm Mylan Pharmaceuticals said it has launched tenofovir alafenamide tablets under the brand name 'HepBest', used for the treatment of chronic hepatitis B in adults, in India.
HepBestTM is the first drug in eight years to be approved for the management of chronic hepatitis B in India, Mylan Pharmaceuticals Pvt Ltd said in a statement.
The tablet has been launched in the strength of 25 mg, it added.
Commenting on the development, Mylan India and Emerging Markets President Rakesh Bamzai said: "Mylan continues to be in the forefront of introducing new treatment regimens for the management of hepatitis in India."
By bringing the best-in-class drug for hepatitis B management, HepBestTM, to India, Mylan hopes to provide care for chronic hepatitis B patients and improve overall management of the disease, he added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd